Ablation of CD226 on CD4+ T cells modulates asthma progress associated with altered IL-10 response and gut microbiota

Int Immunopharmacol. 2023 May:118:110051. doi: 10.1016/j.intimp.2023.110051. Epub 2023 Mar 28.

Abstract

To investigate the role of the costimulatory molecule CD226 in asthma pathogenesis, we produced a CD4+ T-cell-specific CD226 knockout mice model (Cd226ΔCD4) and induced airway allergic inflammation by administering ovalbumin (OVA). Our results revealed alleviated lung inflammation, decreased levels of OVA-specific IgE, and increased levels of IL-10 in the serum of Cd226ΔCD4 mice (P < 0.05). Moreover, IL-10 levels in CD4+ T cells were significantly elevated in the mediastinal lymph node, spleen, and Peyer's patches in the Cd226ΔCD4 mice compared with those in controls (P < 0.05 to P < 0.01). Notably, there was a significantly higher IL-10 mRNA levels in the large intestine of the mice (P < 0.05). The protective effect of CD226 deficiency is also associated with the accumulation of gut TCRγδ+ intraepithelial lymphocytes and reversion of the gut microbiome dysbiosis. The Bacteroidetes-to-Firmicutes ratio and the abundance of Akkermansia increased in the absence of CD226 after OVA treatment. Our data reveal the synchronous changes in the lung and intestine in OVA-treated CD226-knockout mice, supporting the gut-lung axis concept and providing evidence for novel therapeutic approaches for asthma.

Keywords: Asthma; CD226; Gut microbiota; IL-10; Intestinal intraepithelial lymphocytes; T cell.

MeSH terms

  • Animals
  • Asthma* / drug therapy
  • Bronchoalveolar Lavage Fluid
  • CD4-Positive T-Lymphocytes
  • Cytokines / therapeutic use
  • Disease Models, Animal
  • Gastrointestinal Microbiome*
  • Interleukin-10 / genetics
  • Interleukin-10 / therapeutic use
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Ovalbumin / therapeutic use

Substances

  • Interleukin-10
  • Ovalbumin
  • Cytokines